News | Peripheral Artery Disease (PAD) | October 19, 2015

VIVA Physicians Announce Late-Breaking Clinical Trials for VIVA 15 Conference

Annual meeting for vascular medicine and intervention will include presentations on new devices and procedures, plus economic and clinical impacts

VIVA 15 conference, late-breaking clinical trials, VIVA Physicians

October 19, 2015 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the late-breaking sessions at its annual conference, VIVA 2015. Sixteen trial results, featuring the latest in vascular technology and devices, will be released for the first time Nov. 2-3 at the Wynn Las Vegas.

Presentations of the late-breaking trials (including the embargoed results) will be presented during the General Session and highlighted during press conferences.

Scheduled presentations cover numerous categories, including:

New Devices

  • Autogenous Arteriovenous Fistula Creation for Hemodialysis Access: Preliminary Results of the NEAT Trial
  • First-in-Man Study of the MobiusHD for the Treatment of Resistant Hypertension
  • Results of the VISION (combined imaging/atherectomy) Trial

New Procedures

  • Percutaneous Endovascular Bypass of Long SFA Occlusions: Interim Trial Results

Drug-eluting Stents and Drug Coated Balloons

  • MAJESTIC: DES 12-Month Performance Overall and in Diabetic Patients
  • Results from the IN.PACT Global Study
  • Results from the IN.PACT SFA IDE Trial
  • ILLUMENATE FIH: Two-year Results on the Stellarex DCB without Pre-dilatation
  • The Lutonix Global DCB Registry in Complex Femoro-popliteal Lesions
  • Zilver PTX Post-Market Surveillance Study in Japan: 24 Month Results

Aortic Aneurysm Repair

  • Least Invasive Fast-track EVAR: Midterm Results of the Multicenter LIFE registry
  • Endovascular Repair in Acute Type B Aortic Dissection: Two-year Results from the Valiant US-IDE Study
  • Four-Year Results Evaluating the Safety and Effectiveness of the Ovation System

Economic & Clinical Impact

  • DURABILITY Iliac & VISIBILITY Iliac Combined Clinical Trials
  • The SAPPHIRE Worldwide Study, the largest CAS experience ever presented
  • Economic Analysis of Endovascular Interventions to Treat Femoro-popliteal Artery Disease

For more information: www.vivaphysicians.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init